

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
28 March 2019 (28.03.2019)



(10) International Publication Number  
**WO 2019/057565 A1**

(51) International Patent Classification:  
C07K 16/24 (2006.01)

(21) International Application Number:  
PCT/EP2018/074523

(22) International Filing Date:  
11 September 2018 (11.09.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
17191988.9 19 September 2017 (19.09.2017) EP

(71) Applicant: **TILLOTTS PHARMA AG** [CH/CH]; Baslerstrasse 15, 4310 Rheinfelden (CH).

(72) Inventor: **FURRER, Esther Maria**; c/o Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden (CH).

(74) Agent: **KALHAMMER, Georg** et al.; Unsöldstr. 2, 80538 München (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODY VARIANTS

(57) Abstract: The present invention relates to antibodies which bind to TNF $\alpha$  and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.



WO 2019/057565 A1